ICS 2018 Scientific Podium Short Oral Session S15

Overactive Bladder 1

Scientific Podium Short Oral Session S15

Speakers
	Thursday 30th August 2018
	09:05 - 10:35
	Hall B Capacity: 400
A Alex Tong-Long Lin ICS Chair C Christopher John Chermansky Local Chair

Session Schedule

09:05

#264 Regional Variation in Diagnostic Testing for Uncomplicated Overactive Bladder in the Female Medicare Population

Vollstedt A¹, Moses R¹, Gormley E A¹
1. Dartmouth-Hitchcock Medical Center
Female, Overactive Bladder, Urodynamics Techniques

09:12

#265 Higher body fat percentage as a is risk factor of overactive bladder at overweight women

Hagovská M¹, Svihra J², Bukova A³, Svihrova V⁴
1. Department of Physiatry, Balneology, and Medical Rehabilitation, Faculty of Medicine, PJ Safarik University, Kosice, Slovak Republic, 2. Department of Urology, Jessenius Faculty of Medicine, Martin, Comenius University Bratislava, Slovak Republic, 3. Institute of Physical Education and Sport, PJ Safarik University, Kosice, Slovak Republic, 4. Department of Public Health, Jessenius Faculty of Medicine, Martin, Comenius University Bratislava, Slovak Republic
Overactive Bladder, Urgency Urinary Incontinence, Urgency/Frequency

09:20

#266 Temporal Summation is Elevated in Women with OAB Reporting High Psychosocial Burden

Reynolds W S¹, Kaufman M R¹, Dmochowski R¹, Bruehl S¹
1. Vanderbilt University Medical Center, Nashville, TN, USA
Overactive Bladder, Urgency Urinary Incontinence, Pathophysiology

09:27

#267 Metabolism of fatty acids and bile acids in plasma are associated with overactive bladder: metabolomics analysis for possible biomarkers and potential targets for new treatments

Mitsui T¹, Kira S¹, Ihara T¹, Sawada N¹, Nakagomi H¹, Shimura H¹, Miyamoto T¹, Tsuchiya S¹, Kanda M¹, Takeda M¹
1. University of Yamanashi
Overactive Bladder, Pathophysiology, Urgency/Frequency, Male, Pre-Clinical testing

09:35

#268 A Phase 4, double-blind, randomized, placebo-controlled, parallel group, multi-centre study to evaluate the efficacy, safety, and tolerability of mirabegron in older adult patients with overactive bladder syndrome (PILLAR)

Wagg A¹, Staskin D², Engel E³, Herschorn S⁴, Kristy R M⁵, Schermer C R⁵
1. University of Alberta, Geriatric Medicine, Edmonton, Alberta, Canada, 2. St Elizabeth’s Medical Center, Division of Urology, Boston, Massachusetts, USA, 3. Bayview Research Group, Valley Village, California, USA, 4. University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, 5. Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA
Overactive Bladder, Gerontology, Incontinence

09:42

#269 Relationship between excess visceral fat accumulation and the development and severity of overactive bladder

Matsuo T¹, Miyata Y¹, Araki K¹, Nakamura Y¹, Sagara Y¹, Ohba K¹, Sakai H¹
1. Nagasaki University Hospital
Overactive Bladder, Urgency/Frequency, Imaging, Nocturia

09:50

#270 Can OnabotulinumtoxinA Improve Symptoms and Quality of Life in All Patients With Overactive Bladder, Regardless of Disease Duration or Body Mass Index?

Chermansky C¹, Rechberger T², Miles-Thomas J³, Hale D⁴, Cardozo L⁵, Orejudos A⁶, Patel A⁷, Herschorn S⁸
1. University of Pittsburgh Medical Center, Pittsburgh, PA, USA, 2. Medical University Lublin, Lublin, Poland, 3. Urology of Virginia, Virginia Beach, Virginia, USA, 4. Urogynecology Associates, pc, Indianapolis, IN, USA, 5. King’s College Hospital, London, UK, 6. Allergan plc, Irvine, CA, USA, 7. Allergan plc, Marlow, UK, 8. University of Toronto, Toronto, ON, Canada
Incontinence, Overactive Bladder, Urgency/Frequency

09:57

#271 Overlap of bowel dysfunction and urinary symptom severity in women with overactive bladder.

Reynolds W S¹, Kaufman M R¹, Dmochowski R¹
1. Vanderbilt University Medical Center, Nashville, TN, USA
Overactive Bladder, Bowel Evacuation Dysfunction, Constipation, Urgency Urinary Incontinence

10:05

#272 Metabolomic analysis of candidate urinary markers of overactive bladder syndrome in an aging female population: Pilot Prospective Study

Mossa A H¹, Shamout S², Cammisotto P³, Campeau L⁴
1. McGill University- Montreal, Canada, 2. McGill University, Jewish General Hospital, Montreal , Canada, 3. Lady Davis Institute- Montreal, Canada, 4. McGill University, Jewish General Hospital- Montreal, Canada
Female, Overactive Bladder, Pathophysiology

10:12

#273 Study of higher than 80 years old patients keeping frailty under the therapy of mirabegron for overactive bladder (HOKUTO study)

Nakagomi H¹, Mitsui T¹, Ihara T¹, Kira S¹, Sawada N¹, Kamiyama M¹, Takeda M¹
1. University of Yamanashi
Overactive Bladder, Gerontology, Quality of Life (QoL), Questionnaire

10:20

#274 Do Health Disparities Exist in the Insured Refractory OAB Patient Population?

Syan R¹, Zhang C¹, Enemchukwu E¹
1. Stanford University
Urgency/Frequency, Urgency Urinary Incontinence, Neuromodulation, Overactive Bladder, Incontinence

10:27

#275 A Relationship between pre-diabetes and overactive bladder -Analysis of a health-screening program in men and women-

Aoki Y¹, Okada M¹, Ito H¹, Kusaka Y¹, Yokoyama O¹
1. University of Fukui
Female, Urgency/Frequency, Overactive Bladder